By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today reported a 13 percent spike in third-quarter revenues, but reduced its earnings guidance for full-year 2011.

For the three months ended Oct. 1, the company saw revenues climb to $454.5 million, up from $401 million a year ago, driven by new instrument systems, including the Acquity H-Class UPLC, UPLC-mass spectrometer solutions, as well as strong TA Instruments product shipments, Douglas Berthiaume, president and CEO of Waters, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.